Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q3 FY2016 Earnings Presentation
12 slides from Alkem Laboratories's earnings presentation, February 2016
Slide 1: Alkem Laboratories Limited Investor Presentation Q3FY16
Alkem Laboratories Limited Investor Presentation Q3FY16 February 2016
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Financial Highlights – Q3FY16 Consolidated
Financial Highlights – Q3FY16 Consolidated All figures in INR mn Net Income from Operations Net Sales – Geographical Split Domestic International 29.0% 28.4% 29.2% 12,747 8,816 3,644 9,878 6,865 2,821 Q3FY15 Q3FY16 Q3FY15 Q3FY16 Q3FY15 Q3FY16 EBITDA PBT 37.6% 35.2% 2,354 2,270 1,711 1,679 YoY Growth
Slide 4: Financial Highlights – 9MFY16 Consolidated
Financial Highlights – 9MFY16 Consolidated All figures in INR mn Net Income from Operations Net sales – Geographical Split Domestic International 35.9% 32.6% 46.3% 38,490 27,613 10,046 28,314 20,817 6,865 9MFY15 9MFY16 9MFY15 9MFY16 9MFY15 9MFY16 EBITDA PBT 140% 127% 6,902 6,812 2,872 3,004 YoY Grow
Slide 5: Business Highlight Q3FY16: India Business
Business Highlight Q3FY16 India Business: Q3FY16 Net Sales of Rs.8,816 million (28.4% growth1 YoY) India sales INRmn 27,613 • India sales contributed 70.8% to total net sales for 8,816 Q3FY16 6,865 20,817 • During the quarter, our secondary sales grew by 18.6% YoY – higher than Indian Pharmaceutical
Slide 6: Business Highlight Q3FY16: India Therapy Performance
Business Highlight Q3FY16 India Business: Therapy Performance during Q3FY16 Established therapeutic Market rank 1 3 3 5 areas of Alkem Market share4 11.6% 5.7% 5.1% 3.7% 18.5% 17.8% 18.6% 17.3% 16.0% 14.5% 13.5% 13.5% Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients
Slide 7: Business Highlight Q3FY16: US Business
Business Highlight Q3FY16 US Business: Q3FY16 Net Sales of Rs. 2,602 million (18.9% growth YoY) US sales • US sales contributed 20.9% to total net sales for INRmn Q3FY16 7,473 2,602 • Filed 2 ANDAs during the quarter, taking the cumulative ANDA filings to 70 and 1 NDA (as on 31st Dec’15) 2,189 5,046
Slide 8: Business Highlight Q3FY16: Other International Markets
Business Highlight Q3FY16 Other International Markets: Q3FY16 Net Sales of Rs.1,041 million (64.8% growth YoY) Other International Markets sales • Company has presence in more than 50 INRmn international markets 2,573 • Other International sales contributed 8.4% to total net sales for Q3FY16 1,819 1
Slide 9: Strategy going forward
Strategy going forward 1 India Sales: Consolidate our leadership position in the acute segment by driving growth in our mega brands 2 India Sales: Increase our market share in the chronic segment through market share acquisition and new product introductions 3 Improve our field force productivity th
Slide 10: Financials – Key P&L items (Consolidated)
Financials – Key P&L items (Consolidated) Particulars (Rs mn) Q3FY16 Q3FY15 YoY 9MFY16 9MFY15 YoY growth growth Net Income from Operations 12,747 9,879 29.0% 38,490 28,314 35.9% Gross Profit 7,658 5,760 33.0% 23,157 15,321 51.1% Gross Profit margin 60.1% 58.3% 60.2% 54.1% EBITDA 2,354 1,711 37.6% 6,
Slide 11: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on 31st December 2015 Non-Institution, 27.32% Promoter & Institution, Promoter Group, 6.04% 66.64% Institution – Mutual Funds, Foreign Venture Capital, Foreign Portfolio Investors and Foreign Institutional Investors Non-Institution – Individuals, B
Slide 12: Thank You
Thank You